Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Story summaryRoche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.